You should see the other guy

From www.bloodjournal.org by guest on June 17, 2017. For personal use only.
insideblood
30 SEPTEMBER 2010 I VOLUME 116, NUMBER 13
● ● ● CLINICAL TRIALS
Comment on Wall et al, page 2241
You
should see the other guy
---------------------------------------------------------------------------------------------------------------Morie A. Gertz
MAYO CLINIC
In this issue of Blood, Wall and colleagues report the use of radiolabeled 11-1F4 to
visualize amyloid deposits.1 This biodistribution study in humans demonstrates
the ability of an antibody to bind to and identify amyloid deposits in vivo.
Typical amyloid palpebral purpura.
iver uptake was seen in a high proportion
of patients, although only 3 actually were
felt to have clinically important hepatic amyloidosis. Unfortunately, 10 of the 18 patients
with renal involvement and 3 of the 18 patients
who had cardiac involvement without renal
involvement had no uptake of the radiolabeled
antibody in the kidney and heart, respectively.
The fact that renal amyloid deposits in tissue
sections (in vitro) immunostained weakly suggests that the antibody itself may not be able to
bind to amyloid deposits in the kidney or heart
and not because of antibody dosage. Despite
these limitations, this report represents an
exciting proof of principle. The imaging paper
builds on previous research from this group
L
where human light-chain–associated tumors
in mice underwent marked regression, without
toxicity, after the administration of the same
antibody.2
If there is to be any hope in improving the
outcomes in patients with amyloidosis, there
has to be a better mechanism for earlier detection of this disease. Not all patients will
present with characteristic physical findings
(see figure).
Diagnostic physical findings of purpura or
glossomegaly are found in only 15% of patients. Clinicians seek the availability of in vivo
imaging that would specifically recognize
amyloid for their patients, when the clinician
suspects the diagnosis but is unwilling to en-
blood 3 0 S E P T E M B E R 2 0 1 0 I V O L U M E 1 1 6 , N U M B E R 1 3
gage in a series of uncomfortable biopsies that
entail a risk of bleeding. Attempts to improve
on the diagnosis of cardiac amyloidosis using
strain rate echocardiography3 as well as cardiac
magnetic resonance imaging4 have recently
been introduced in an attempt to identify cardiac amyloid deposits before significant functional compromise occurs. These are the patients most likely to benefit from
chemotherapy or stem cell transplantation.
The existence of a radio-immunoantibody
capable of imaging amyloid deposits may
prove to be of value in future monitoring of the
disorder after therapy. Current techniques
rely heavily on measurements of changes in
the precursor protein, either the monoclonal
protein in the serum or urine5 or the immunoglobulin-free light chain ratio in serum.6 Although these measures have been shown to
correlate with outcomes, they do not directly
assess what has happened with the actual amyloid deposits in the tissues. Imaging the amyloid burden at diagnosis, using the antibody,
may have important prognostic value. This is
reminiscent of the serum amyloid P (SAP)
scan available in Europe, which can determine
organ involvement and indicate the body amyloid load.7 SAP scintigraphy, which identifies
all forms of amyloid deposits including hereditary and secondary forms, often reveals more
widespread organ involvement than is identified clinically and represents useful additional
information. Unfortunately, the SAP scan is
not available in the United States, and investigators have had to rely on indirect evidence of
organ involvement such as the serum alkaline
phosphatase for liver amyloid, brain natriuretic peptide and troponin levels for cardiac
amyloid, and the level of urinary protein loss
for renal amyloid to assess organ involvement
response and progression.
The therapeutic potential of 11-1F4 cannot be overlooked. Once small tracer doses
identify the deposits, investigation of the antibody’s ability to cause dissolution of the amyloid would be a natural next step. Similar
2199
From www.bloodjournal.org by guest on June 17, 2017. For personal use only.
therapeutic approaches that involved depleting the SAP component have recently been
published.8 Even if the current antibody does
not bind to the heart or the liver, limited organ
regression using an agent with a high therapeutic profile can set the stage for important
immunotherapeutic approaches to the management of this devastating disease with successive generations of antiamyloid antibodies.
Conflict-of-interest disclosure: The author
declares no competing financial interests. ■
REFERENCES
1. Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116(13):2241-2244.
2. Solomon A, Weiss DT, Wall JS. Therapeutic potential
of chimeric amyloid-reactive monoclonal antibody 11-1F4.
Clin Cancer Res. 2003;9(10 Pt 2):3831S-3838S.
3. Sun JP, Stewart WJ, Yang XS, et al. Differentiation of
hypertrophic cardiomyopathy and cardiac amyloidosis from
other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;
103(3):411-415.
4. Syed IS, Glockner JF, Feng D, et al. Role of cardiac
magnetic resonance imaging in the detection of cardiac
amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):
155-164.
5. Mollee P. Current trends in the diagnosis, therapy and
monitoring of the monoclonal gammopathies. Clin Biochem
Rev. 2009;30(3):93-103.
6. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008;141(4):413-422.
7. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN,
et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med. 2007;48(6):
865-872.
8. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148(5):760-767.
● ● ● MYELOID NEOPLASIA
Comment on Isakson et al, page 2324
A---------------------------------------------------------------------------------------------------------------new oncoprotein catabolism pathway
Valérie Lallemand-Breitenbach and Hugues de Thé
INSERM/CNRS/UNIVERSITÉ PARIS DIDEROT
In this issue of Blood, Isakson et al identify autophagy as a new pathway for therapyinduced PML/RARA degradation, a critical determinant for leukemia eradication.
Schematic representation of the 4 pathways implicated in PML/RARA degredation by retinoic acid or arsenic
trioxide (see text for details).
cute promyelocytic leukemia (APL) is
characterized by the t(15;17) chromosomal translocation that fuses the promyelocytic leukemia (PML) gene with that of retinoic acid receptor A (RARA). This rare acute
myeloid leukemia exhibits a differentiation
block at the promyelocytic stage of granulo-
A
2200
cytic maturation, hence its name. APL is a
paradigm for oncoprotein-targeted therapy.
Indeed, at the molecular level, the 2 clinically
active therapies, all trans-retinoic acid
(ATRA) and As2O3, both induce the degradation of the PML/RARA fusion protein.
ATRA degrades both RARA and PML/
RARA, while conversely As2O3 degrades both
PML and PML/RARA. Thus, these 2 serendipitously discovered agents actually target
each of the 2 constitutive moieties of the oncoprotein (see figure). Several lines of evidence,
among which is the synergistic effect of the
ATRA/As2O3 combination for APL eradication in mice and man, have strongly implicated
PML/RARA degradation in disease
clearance.1-3
PML/RARA is a transcriptional repressor
that binds both RARA response elements and
de novo DNA sequences, resulting in
dominant-negative and gain-of-function
properties. Pharmacologic ATRA concentrations release PML/RARA-mediated transcriptional repression and induce differentiation. PML/RARA also disrupts structures
formed by the normal PML protein, PML
nuclear bodies. These enigmatic domains have
been repeatedly implicated in control of cell
death or self-renewal of normal or leukemia
stem cells.4 Treatment-induced PML/RARA
degradation reverses these effects, allowing
differentiation and loss of clonogenic activity,
as shown by transplantation studies in mice,
culminating in APL eradication.2,3,5
Previous studies had identified 3 distinct
pathways for therapy-induced PML/RARA
degradation. The first one is cleavage of the
PML moiety of PML/RARA by proteases
activated by ATRA-induced differentiation.6
A second ATRA-initiated catabolic pathway
activates direct proteasome-dependent degradation of DNA-bound, hormone-activated
RARA or PML/RARA,7 a feedback mechanism conserved for all nuclear receptors. Finally, As2O3 targets the PML part of the fusion protein and specifically induces a SUMOdependent ubiquitin-mediated degradation
process that was recently elucidated at the
biochemical and cellular level.8
In the accompanying report,9 a fourth
pathway, autophagy, was conclusively implicated in both ATRA- and As2O3-mediated
PML/RARA degradation. The authors first
demonstrate that PML/RARA is a highly
insoluble protein. Misfolded proteins form
aggregates that are often cleared by autophagy
within the cytoplasm. The authors thus examine the consequence of activation or inhibition
of autophagy on PML/RARA stability and
observe that this process regulates basal
PML/RARA protein levels. Importantly,
both ATRA and As2O3 activate autophagy and
30 SEPTEMBER 2010 I VOLUME 116, NUMBER 13
blood
From www.bloodjournal.org by guest on June 17, 2017. For personal use only.
2010 116: 2199-2200
doi:10.1182/blood-2010-06-289926
You should see the other guy
Morie A. Gertz
Updated information and services can be found at:
http://www.bloodjournal.org/content/116/13/2199.full.html
Articles on similar topics can be found in the following Blood collections
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Copyright 2011 by The American Society of Hematology; all rights reserved.